Numinus rolls out the list of Advisors on its psychedelics Advisory Council

Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.

A Washington, D.C. councilman introduced a bill this week that would expand opportunities for formerly incarcerated people to participate in the medical marijuana market.

Field Trip’s new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.

Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.

Mind Cure adds an expert in neuroscience and nutrition to its Advisory Board.

New Jersey voters support cannabis legalization in the state by a two-to-one margin, according to an Farleigh Dickson University poll released October 9.

The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.

Industry heavyweight Compass Pathways launched the current rally in psychedelic stocks. But four other stocks have been outperforming CMPS.

Field Trip Psychedelics is targeting a $16 billion treatment market with its ketamine-assisted psychotherapy clinics.